Navigation Links
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard - IPM) to treat advanced sarcoma patients was presented at the European Society of Medical Oncology (ESMO) meeting held July 5-8, 2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/II Study of IPM (ZIO-201) In Advanced Sarcoma," was presented by Rashmi Chugh, MD, a Principal Investigator from the University of Michigan, Ann Arbor, Michigan.

The trial has now enrolled 39 patients and this presentation reports on the first 10 evaluable patients. Of these 10 heavily pretreated patients (median 4 prior regimens), 1 has a partial response (21 weeks and ongoing) and 4 have stable disease. Of these 5 patients, 2 had progressed through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients.

"Ifosfamide is one of the few effective standard therapies available for most sarcomas," commented Dr. Chugh. "Having a novel drug that could offer the benefits of high-dose ifosfamide without the debilitating side effects, particularly the bone marrow suppression and neurotoxicity, would be of great benefit in the treatment of this disease. We are enthusiastic about these early results and we look forward to further elucidating the overall impact of ZIO-201 in this setting."

The Company expects to report more complete data at upcoming medical meetings, including the 14th European Cancer Conference (ECCO) taking place in Barcelona from September 23-27, 2007.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... Test builds on company,s suite of tests to ... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... new diagnostic assay designed to help physicians better ... infections. The company will introduce the Pneumococcal ...
... of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI ... Given With Standard Platelet TherapyKENILWORTH, N.J., March 12 ... ) Phase II trial of SCH 530348, a novel ... The Lancet and demonstrated that the investigational ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
(Date:7/29/2014)... Regardless of the good things that happen in ... those with. Love is about understanding, commitment and sharing ... also about overcoming all the challenges that a relationship ... women need to know how to understand guys. ... please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 . ...
(Date:7/29/2014)... Daily Gossip indicates in its Acne No More ... beautiful and clear skin in just 30 to 60 days. ... results even sooner than that. The new method was created ... step by step program, too. , Mike Walden claimed ... battled this condition for a decade and none of the ...
(Date:7/29/2014)... (HealthDay News) --,The time at which heart attack patients ... survival, new research suggests. Showing up at the ... is associated with a 13 percent higher risk for ... Every year, more than 250,000 people suffer a ... heart attack, which is caused by a complete blockage ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Chlorine helps keep pool ... likely to develop eye infections, doctors say. ... well as blurry vision, said Dr. Sampson Davis, an ... New Jersey. It,s important to understand why this ... away the outer film layer of the eye that ...
Breaking Medicine News(10 mins):Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2
... serious complications, researchers say , THURSDAY, Oct. 22 (HealthDay ... scans are better than standard X-rays at detecting the ... known as swine flu. , Researchers examined seven patients ... all of them. Three of the patients also received ...
... social interaction, researchers say , WEDNESDAY, Oct. 21 (HealthDay ... with autism has been identified by U.S. researchers, who ... diagnose and treat the disorder. , This genetic signature ... to the way that genes are switched on and ...
... to new treatments , WEDNESDAY, Oct. 21 (HealthDay News) ... that the gene behind Gaucher disease, a rare neurological ... those of us who work with rare disorders, it ... applicable to more common disorders," said Dr. Ellen Sidransky, ...
... women have tougher time shedding those excess pounds, study finds ... gain more than 15 pounds during pregnancy tend to retain ... finds. , Oregon researchers collected data on almost 1,700 obese ... gave birth between 2000 and 2005. , "We found that ...
... plans to rethink testing for breast, prostate tumors, contrary ... -- The American Cancer Society says it is not ... widely reported Wednesday. , "We are not redoing or ... going to restate our guidelines to emphasize the inadequacies ...
... Ohio It was once thought that the two communities ... cells and the normal cells that surround them existed ... cells encouraged cells within the tumor to become malignant, but ... new study led by Ohio State University cancer researchers published ...
Cached Medicine News:Health News:Less Sensitivity to Hormone May Play Role in Autism 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 2Health News:Gene Behind Gaucher Disease a Player in Parkinson's 3Health News:For Obese, Weight Gained in Pregnancy May Not Leave 2Health News:For Obese, Weight Gained in Pregnancy May Not Leave 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 2Health News:American Cancer Society Stands By Cancer Screening Guidelines 3Health News:American Cancer Society Stands By Cancer Screening Guidelines 4Health News:Study shows how normal cells influence tumor growth 2
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
Medicine Products: